By Chris Wack
Pliant Therapeutics shares were halted in early morning trading after falling 25% to $2.57, after the company said it is discontinuing a phase 2b trial for bexotegrast in patients with idiopathic pulmonary fibrosis.
The discontinuation follows a prespecified data review and recommendation by an independent Data Safety Monitoring Board, as well as a secondary review and recommendation by an outside expert panel.
The late-stage biopharmaceutical company said that while an imbalance in unadjudicated IPF-related adverse events between the treatment and placebo groups led to the discontinuation of the trial, early evidence of efficacy on the forced vital capacity endpoint was also observed.
Overall, the percentage of IPF-related adverse events in both dose groups was comparable--about 10%.
The company plans to analyze the complete data from the trial and evaluate next steps for bexotegrast's development, including additional dose-ranging Phase 2b studies with lower doses in pulmonary fibrosis.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
March 03, 2025 09:47 ET (14:47 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。